Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Celsion (CLSN) Presents at Rodman & Renshaw Conference

Celsion Corporation (NASDAQ: CLSN), a fully-integrated oncology company, is focused on developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The company’s lead program is ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in phase III development for the treatment of primary liver cancer and phase II development for the treatment of recurrent chest wall breast cancer. For more information, visit the company’s website at

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. For more information on Rodman & Renshaw, visit
This entry was posted in Rodman and Renshaw Conference. Bookmark the permalink.

Comments are closed.